Acceptable Incremental Cost Effectiveness Ratio for Use of New Drugs, Cases in Statin Therapies

DOI Web Site Web Site PubMed 3 References Open Access
  • NAKAO Susumu
    Social and Administrative Pharmacy Science Unit, School of Pharmacy, Nihon University
  • KAWABE Hiroyuki
    Social and Administrative Pharmacy Science Unit, School of Pharmacy, Nihon University
  • TAKUMA Hiroki
    Social and Administrative Pharmacy Science Unit, School of Pharmacy, Nihon University
  • SHIRAGAMI Makoto
    Social and Administrative Pharmacy Science Unit, School of Pharmacy, Nihon University

Search this article

Description

  As it is an urgent issue to contain increasing healthcare expenditures, unlimited reimbursement of pharmaceuticals continues to be controversial. The objective of this study is to identify acceptable incremental cost effectiveness ratios between new and conventional therapies. Clinical study data for five statin therapies were used to indicate treatment effectiveness and incremental costs were indicated by price premiums at price listing. The incremental cost effectiveness ratios to pravastatin were 0 yen/patient with response, 1,475.1 yen/patient with response, 3,033.3 yen/patient with response, and 3,032.4 yen/patient with response. By conducting further analyses in various pharmaceuticals and categorizing acceptable incremental cost effectiveness ratios based on the disease severity and expected level of improvement in disease condition, drug prices that reflect the value of new pharmaceuticals and that are reasonable to be reimbursed can be suggested.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 130 (10), 1347-1352, 2010-10-01

    The Pharmaceutical Society of Japan

References(3)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top